Medidata Rave Electronic Data Capture and Management Solution Selected by Leading Pharmaceutical Company

Medidata Solutions today announced that AstraZeneca (NYSE: AZN)
has chosen to standardize on Medidata Rave(R) electronic clinical data
capture (EDC), management and reporting solution as part of a plan to
fully migrate to paperless clinical trials. Medidata Rave will help
AstraZeneca replace its in-house EDC system and other EDC products for
studies across all therapeutic categories in its diverse portfolio.
AstraZeneca plans to implement Medidata Rave in many of its studies
worldwide.

As an early adopter of EDC technology, AstraZeneca previously
relied on an in-house solution and has gained experience with other
vendor solutions over the past five years. In 2005, AstraZeneca
conducted an intensive review of a number of EDC products, which
involved an evaluation of key requirements including functionality
fit, the best fit with AstraZeneca's strategic process, total cost of
ownership, ease-of-use, and product look and feel. Medidata Rave met
the highest percentage of AstraZeneca's requirements and was selected
for its strong architectural base, new technology, and user-friendly
platform.

"When it came down to it, the decision was clear. We needed a tool
that would grow alongside us, rather than force us to make changes
that would ultimately impact our user base," said Robert Mullen,
Global Project Leader for Medidata Rave Implementation at AstraZeneca.

"AstraZeneca has high expectations for Medidata and Rave," said
Anders Ekblom, Vice President and head of Clinical Development at
AstraZeneca. "When implemented, we look forward to achieving
significant improvement in clinical efficiency, with the goal of
improving overall time to market."

"We are delighted to strengthen our relationship with AstraZeneca,
one of several of the world's leading pharmaceutical companies that
have recently decided to standardize on Medidata Rave," said Tarek
Sherif, CEO of Medidata Solutions. "AstraZeneca's selection of
Medidata Rave speaks to our ability to scale to accommodate any size
company or trial and implement our solution as any sponsor's standard
for a web-based data capture system. We look forward to supporting
AstraZeneca's efforts to go paperless and achieve truly global
electronic clinical trials."

About Medidata Solutions Worldwide

Medidata Solutions helps the world's leading pharmaceutical,
biotechnology, medical device, and research organizations maximize the
value of their clinical research investments. Innovative process
design, technology and services streamline clinical trials by
providing early visibility to reliable clinical data - the lifeblood
of every research organization. Working with companies and
institutions both large and small, Medidata Solutions helps clinical
researchers safely accelerate the process of bringing life-enhancing
treatments to market - on five continents and in more than 70
countries. Medidata Solutions brings significant value to its broad
client base with deep clinical experience and expertise in more than
20 therapeutic areas, projects in Phase I, II, III, IV, registries and
surveillance, and studies with thousands of investigators and
tens-of-thousands of subjects. For more information, please visit
www.mdsol.com.

About AstraZeneca

AstraZeneca (NYSE: AZN) is a major international healthcare
business engaged in the research, development, manufacture and
marketing of prescription pharmaceuticals and the supply of healthcare
services. It is one of the world's leading pharmaceutical companies
with healthcare sales of $23.95 billion and leading positions in sales
of gastrointestinal, cardiovascular, neuroscience, respiratory,
oncology and infection products. In the United States, AstraZeneca is
a $10.77 billion healthcare business with more than 12,000 employees.
AstraZeneca is listed in the Dow Jones Sustainability Index (Global)
as well as the FTSE4Good Index. For more information about
AstraZeneca, please visit: www.astrazeneca.com.